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Prevention of acute deaths in mice after very high dose
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Summary Very high dose cyclophosphamide (Cy) (500-600mgkg-1) given by single bolus i.p. injection in
mice caused acute deaths in all animals within 48h of treatment (0/10 survivors). These acute deaths were
abolished or very significantly reduced if Cy was administered in divided dosage over 8 h (10/10 survivors) or
12h (14/15 survivors). The effect was maintained at doses of up to 600mgkg-1 administered in divided
dosage over 24h (15/15 survivors). In 2 human small cell carcinoma xenografts anti-tumour efficacy was not
diminished by divided dosage. In both xenografts tumour growth delay was enhanced, although not
significantly so, when treated with divided dosage compared with single dose, and in one of the xenografts 3
complete remissions were achieved with divided dosage compared with none after single dosage. It is
postulated that the underlying mechanism concerns diminished cardiotoxicity. These results may have
significance in clinical studies investigating very high dose Cy.
Cyclophosphamide (Cy) is toxic to several
important normal tissues including bone marrow
(Anders & Kemp, 1961), urothelium (Philips et al.,
1961), lung in mice (Collis et al., 1980) and
occasionally in man (Collis, 1980), and at very high
doses, cardiac muscle (Mills & Roberts, 1979). This
toxicity is dose related, and in mice the time of
death after lethal dosage also depends on the dose
administered. At doses of Cy of up to 450mgkg-1
our studies show that most deaths occur between
days 3-10 post-treatment. This corresponds to the
presence of Cy induced neutropenia and urothelial
damage (personal observation). At this dosage
however some later deaths are also seen from about
day 20 onwards and this corresponds to the period
of respiratory distress and histologically
demonstrated lung damage (Collis et al., 1980).
At doses of Cy >450mgkg-1, mice die within a
few hours of treatment, and it has been suggested
that these deaths are associated with cardiac
damage (Kovacs & Steinberg, 1972). Similar acute
deaths have been observed in dogs and have been
shown at necropsy to be associated with cardiac
damage (O'Connell & Berenbaum, 1972). Acute
cardiac deaths occurring within a few days of very
high dose Cy treatment have also been reported in
man (Mills & Roberts, 1979).
In this paper, we describe attempts to prevent
these acute deaths associated with very high dose
Cy by administering the drug in divided dosage.
We also describe the effects of such treatment on
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two human small cell carcinoma xenografts grown
in immune deprived mice.
Materials and methods
Mice
C57BL mice bred at the Institute of Cancer
Research, Pollards Wood, were used for all normal
tissue studies.
CBA/lac mice immune suppressed by
thymectomy at 4 weeks of age followed 4 weeks
later by 9Gy whole body irradiation were used for
human tumour xenograft studies. The mice were
pre-treated with cytosine arabinoside 2 days before
the total body irradiation in order to enhance bone
marrow recovery, as previously described (Steel et
al., 1978).
Human tumour xenograft studies
Two human small cell carcinoma xenografts HX69
and HX72 originally established from material
obtained by surgical biopsy were used in these
studies. The tumours were in early passage, from
serial passages 6-14, and had been shown to retain
their human histological and chromosomal
characteristics, and to have therapeutic responses to
cytotoxic drugs similar to that seen in the patients
from which the original biopsies were obtained
(Shorthouse et al., 1980). At the start of each
experiment tumour fragments measuring 2-3mm.
were bilaterally implanted s.c. into the flanks of 8-
10 weeks old immune-suppressed CBA/lac mice.
Tumour growth delay experiments were begun
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when tumours had reached a volume of 0.3-0.5 cm3
calculated by the formula V=nLD2/6 where V is
volume, L is the longest diameter and D is the
diameter at right angles to this. At first
measurement (Vo) the tumours were ranked
according to size and allocated to control or
treatment groups to ensure that each group
contained the same spectrum of tumour sizes.
Cyclophosphamide
Pure Cy monohydrate (Koch-Light Ltd.) was made
up in saline and administered by i.p. bolus injection
in a volume of 0.01 mlg-1 mouse wt for doses
below 350mgkg-1 and 0.02mlg-1 mouse wt for
doses above this.
Survival
Survival, in normal tissue experiments, was
measured for up to 56 days post-treatment.
Tumour growth delay
The growth rates of individual tumours were
measured by comparing the volume at time t (Vt)
with its volume at the beginning of the experiments
(Vo). The value Vt/Vo was calculated for each
group. When a death occurred or a tumour
completely regressed that animal or tumour was
excluded from any further calculation. Complete
tumour remission was defined as complete
disappearance of tumour which persisted until the
end of the experiment.
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Statistics
In order to establish the significance of tumour
growth delay differences, individual times taken for
tumours to re-grow to treatment volume were
ranked and the non-parametric Mann-Witney U
test was used to obtain a P value. The significance
of differing animal survivals was calculated using
the "Fisher's exact test".
Results
Survival studies
Figure 1 shows that Cy induced deaths up to a
total dose of 450mgkg-1 usually occur either
between Day 3 and Day 10 or after Day 20.
However, at a dose of 500 mgkg1 all deaths occur
within 48 h of treatment.
Figure 2 shows that if 500mgkg 1 Cy was given
as 5 equally spaced 100mgkg- doses over an 8h
period, no animals died within 48h of treatment,
but all were dead by Week 4. Previous studies have
already shown that these late deaths can be reduced
by Cy pre-treatment (Millar & McElwain, 1978),
and it can be seen that when a pre-treatment dose
of Cy (50mgkg-1) was administered 4 days before
the divided dose, survival was further prolonged
and 2 mice remained alive 8 weeks later.
Table I confirms that the very acute deaths which
occur following treatment with Cy 500mgkg-1 are
avoided by dose scheduling, this time over 12h: no
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Figure 1 Time ofdeath and survivors, following various doses of cyclophosphamide.
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Figure 2 Mouse survival after treatment with Cy
500mgkg-1 administered either as a single dose or
split as 5xlOOmgkg-1 doses over 8h. 0 Cy
500mgkg-1 stat no prime; 0 Cy 500mgkg-
stat+Cy50mgkg 1 4 days earlier; * Cy 500mgkg-1
in divided doses no prime; O Cy 500mgkg1 in
divided doses+Cy 50mgkg-1 4 days earlier.
Table I Mouse survival 3 days and 8 weeks after
treatment with Cy 500mgkg-1 administered either as a
single stat dose, or as 7 equally spaced doses over 12h
3 day 8 week
Method ofadministration survival survival
Cy 500mgkg-1 stat. 0/10 0/10
No pre-treatment.
Cy 500mgkg 1 stat. 0/10 0/10
Cy 50mgkg 1 4 days earlier
Cy 500mgkg- in divided doses 14/15 0/15
over 12h. No pre-treatment.
Cy 500mgkg 1 in divided doses 15/15 14/15
over 12h+Cy. 50mgkg-1 4
days earlier.
P<0.001 P= <0.001
mice survived more than 72h when the total dose
was administered as a single injection whether pre-
treated or not. However 14/15 non pre-treated and
15/15 pre-treated mice were still alive 72h after
completion of therapy when the drug was
administered as 7 equally spaced smaller doses over
12h. Eight weeks after therapy all the non pre-
treated divided dose group had died whereas 14/15
of the pre-treated divided dose group remained
alive (P= <0.001).
Table II shows that only 4/15 pre-treated mice
survived for 72h after a dose of Cy 600mgkg-1
administered over 12h, whereas all 15 pre-treated
mice survived 72h when the drug was administered
over 24h. Eight weeks after therapy 7 of the group
which received the drug over 24h remained alive
Table II Survival of pre-treated mice 3 days and 8 weeks
after treatment with Cy 600mgkg- administered in
divided doses over 12 or 24h
3 day 8 week
Method ofadministration survival survival
Cy 600mgkg-1 (5 x 120mgmg-1) 4/15 0/15
over 12h+50mgkg-1 4 days
earlier.
Cy 600mgkg-1 (10 x60mgkg-1) 15/15 7/15
over 24h+50mgkg-1 4 days
earlier.
P<0.001 P<0.01
compared with none of the group which received
the drug over 12h (P= <0.01).
Human tumour xenograft studies
Figure 3 shows the tumour growth delay achieved
in human small cell carcinoma xenograft HX69
treated with 200mgkg- Cy given either as a single
injection or in 10 equally spaced 20mgkg-1 doses
over a 24h period (all mice received a pre-treatment
dose of 50mgkg- 1 4 days earlier). Although
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Figure 3 Response of human small cell carcinoma
xenograft. HX69 to Cy 200mgkg-1. A Untreated
mice; * Cy 200mgkg- stat Day 6+50mgkg-1 Day
2; O Cy 200 mgkg-1 divided dose Day 6+50 mgkg -
Day 2.
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tumour growth delay was slightly greater in the
animals treated by divided dosage, this difference
was not statistically significant. One animal treated
by single dosage died, compared with no animals
treated by divided dosage.
Figure 4 shows tumour growth delay in human
small cell carcinoma xenograft HX72 treated with
Cy 300mgkg-1 either as a single injection or over
a 24h period as described above (both groups were
pre-treated with Cy 50mgkg-' 4 days earlier). No
significant difference in tumour growth delay was
seen between the two treatments. Seven out of 9
animals treated with single dose died compared
with 5/9 treated with divided dosage. No complete
tumour remissions were seen in animals treated
with stat dosage compared with 3/15 complete
tumour remissions treated by divided dosage.
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Figure 4 Response of human small cell carcinoma
xenograft Hx72 to Cy 300mgkg-1. (A) Untreated
mice; (U) Cy 300mgkg'- stat Day 6+50mgkg-1
Day 2; (C]) Cy 300mgkg-' divided dose Day
6+50mgkg-' Day 2.
mechanism of this effect is uncertain but may
reflect diminished cardiotoxicity. Kovacs &
Steinberg (1972) have suggested that the respiratory
distress associated with the acute deaths following
treatment with very high doses of Cy is caused by
cardiac damage and it is well established that
similar deaths in dogs 6-8 h after treatment is
associated with haemorrhagic necrosis of the
myocardium (O'Connell & Berenbaum, 1974). In
man too, acute cardiac deaths have been reported
within a few hours of treatment with doses of
220mgkg-1 or greater, and at least once with only
144mgkg-1 (Mills & Roberts, 1979). Doses as low
as 60mgkg-1 have been associated with a transient
rise in cardiac enzymes and ECG changes (Buckner
et al., 1974). Histological studies have so far failed
to confirm myocardial changes in our mice, but this
may not be unexpected in view of the very short
time interval involved.
Divided dose scheduling does not in itself allow
long term survival, for although the mice survive
the initial very acute toxicity, they later succumb to
the other normal tissue toxicities associated with Cy
treatment. These later toxicities, but not the very
acute toxicity, can to a large extent be overcome by
the method of Cy pretreatment as previously
described (Millar & McElwain, 1978).
Critically, no loss of anti-tumour efficacy was
observed with divided dose scheduling against 2
human small cell carcinoma xenografts. Indeed
there was the suggestion that such scheduling had
an enhanced effect with 3 complete remissions for
HX72 compared with none after single dose
therapy. Thus this technique achieves an enhanced
therapeutic ratio for Cy, first in that the same
dosage can be administered with significantly less
fatal toxicity but with at least as good anti-tumour
effect, and second in that significantly larger doses
with appropriate increase in anti-tumour effect can
be administered before the same fatal toxicity is
reached.
Recently there has been considerable interest in
the clinical use of high dose Cy to treat several
human tumour types including small cell lung
cancer and ovarian cancer (Souhami et al., 1982,;
Buckner et al., 1974). We are hopeful that divided
dose scheduling may be useful clinically, and a pilot
study based on these experiments is now in progress
(Smith et al., 1983).
Discussion
These studies demonstrate that the acute deaths
which occur in mice within 48h of treatment with
very high dose Cy can be prevented if the drug is
given in divided doses over an 8-24h period. The
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